Structural characterization of prazosin hydrochloride and prazosin free base

Journal of Pharmaceutical Sciences

Volumn 93, Issue 12, 2004, Pages 3090-3095

  Chernyshev, Vladimir V ^a   Stephens, Peter W ^b   Yatsenko, Alexandr V ^a   Ryabova, Olga B ^c   Makarov, Vadim A ^c  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b STONY BROOK UNIVERSITY   (United States)

^c Department of Medicinal Chemistry   (Russian Federation)

Author keywords

Ab initio calculations; Crystal structure; Structure activity relationship (SAR); X ray powder diffractometry

Indexed keywords

PRAZOSIN;

ARTICLE; CALCULATION; CHEMICAL MODIFICATION; CRYSTAL STRUCTURE; CRYSTALLIZATION; CRYSTALLOGRAPHY; DRUG STRUCTURE; PROTON TRANSPORT; STRUCTURE ACTIVITY RELATION; X RAY POWDER DIFFRACTION;

EID: 10644262247     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20204     Document Type: Article

References (34)

1. Hess H-JP. 1970. 2,4,6,7-Tetra substituted quinazolines. US patent 3511836.
2. Bianco EJ. 1978. Novel crystalline forms of prazosin hydrochloride. US patent 4092315.
3. Lindholm SOE. 1988. Anhydrous, stable, crystalline δ-form of prazosin hydrochloride. US patent 4739055.
4. Schickaneder H, Grafe I, Kurt H. 1989. Crystalline, anhydrous sigma-form of 2-(4-(2-furoyl)-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxy-quinazoline hydrochloride and a process for its preparation. US patent 4816455.
5. Niimoto Y, Yoshida S. 1991. Preparation of prazosin hydrochloride anhydrous epsilon-type crystals. JP patent 03206088.
6. 1-Adrenoceptor subtypes. Eur J Pharmacol 375:261-276.
7. Hiraoka Y, Taniguchi T, Tanaka T, Okada K, Kanamaru H, Muramatsu I. 2003. Pharmacological characterization of unique prazosin-binding sites in human kidney. Naunyn Schmiedebergs Arch Pharmacol 368:49-56.
8. 1-acid glycoprotein: Generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the a variant. Mol Pharmacol 54:129-138.
9. Yoshida F, Topliss JG. 2000. QSAR model for drug human oral bioavailability. J Med Chem 43:2575-2585.
10. Saiakhov RD, Stefan LR, Klopman G. 2000. Multiple computer-automated structure evaluation model of the plasma protein binding affinity of diverse drugs. Perspectives Drug Discovery Des 19:133-155.
11. Oprea TI, Gottfries J. 2000. Toward minimalistic modeling of oral drug absorption. J Mol Graph Model 17:261-274.
12. 1-adrenergic antagonists. J Med Chem 43:2770-2774.
13. 1-adrenergic receptor subtypes by molecular modeling. Life Sci 71:2531-2541.
14. Bergstrom CAS, Norinder U, Luthman K, Artursson P. 2002. Experimental and computational screening models for prediction of aqueous drug solubility. Pharm Res 19:182-188.
15. 1-adrenoceptor antagonists and antihypertensive agents. J Med Chem 30:999-1003.
16. Bontchev PR, Ivanova BB, Bontchev RP, Mehandjiev DR. 2001. Complexes of Cu(II) with 1-(4-amino-6, 7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)- piperazine (prazosin): Synthesis, properties, crystal structure. Polyhedron 20:231-236.
17. David WIF, Shankland K, McCusker LB, Baerlocher Ch, editors. 2002. Structure determination from powder diffraction data. Oxford, UK: Oxford University Press.
18. Le Bail A. 1993-2003. Structure determination from powder diffraction database. http://www.cristal.org/iniref.html.
19. Harris KDM, Tremayne M, Kariuki BM. 2001. Contemporary advances in the use of powder X-ray diffraction for structure determination. Angew Chem Int Ed Engl 40:1626-1651.
20. Chernyshev W. 2001. Structure determination from powder diffraction. Russ Chem Bull Int Ed 50:2273-2292.
21. Pippuri AK, Honkanen EJ. 1980. Method for the production of 6,7-dimethoxy-4-amino-2-(4-(2-furoyl)-1-piperazinyl)quinazoline having an anti-hypertensive effect. CA patent 1092117.
22. Werner P-E, Eriksson L, Westdahl M. 1985. TREOR, a semi-exhaustive trial-and-error powder indexing program for all symmetries. J Appl Cryst 18:367-370.
23. Zlokazov VB. 1992. MRIAAU: A program for auto-indexing multiphase polycrystals. J Appl Cryst 25:69-72.
24. Zlokazov VB. 1995. AUTOX: A program for auto-indexing reflections from multiphase polycrystals. Comput Phys Commun 85:414-422.
25. Young RA, Wiles DB. 1982. Profile shape functions in Rietveld refinements. J Appl Cryst 15:430-438.
26. Pawley GS. 1981. Unit-cell refinement from powder diffraction scans. J Appl Cryst 14:357-361.
27. Chernyshev W, Schenk H. 1998. A grid search procedure of positioning a known molecule in an unknown crystal structure with the use of powder diffraction data. Z Kristallogr 213:1-3.
28. Zlokazov VB, Chernyshev VV. 1992. MRIA: A program for a full profile analysis of powder multiphase neutron-diffraction time-of-flight (direct and Fourier) spectra. J Appl Cryst 25:447-451.
29. Chernyshev VV, Machon D, Fitch AN, Zaitsev SA, Yatsenko AV, Shmakov AN, Weber H-P. 2003. Protonation site and hydrogen bonding in anhydrous and hydrated crystalline forms of doxazosin mesylate from powder data. Acta Crystallogr B 59:787-793.
30. Laikov DN. 1997. Fast evaluation of density functional exchange-correlation terms using expansion of electron density in auxiliary basis sets. Chem Phys Lett 281:151-154.
31. Becke AD. 1988. Density-functional exchange-energy approximation with correct asymptotic behavior. Phys Rev A 38:3098-3100.
32. Lee CT, Yang WT, Parr RG. 1988. Development of the Colve-Salvetti correlation-energy formula into a functional of the electron density. Phys Rev B 37:785-789.
33. Geene J, Kahn S, Savoj H, Spraque P, Teig S. 1994. Chemical functional queries for 3D database search. J Chem Inf Comput Sci 34:1297-1308.
34. Giardinà D, Gulini U, Massi M, Piloni MG, Pompei P, Rafaiani G, Melchiorre C. 1993. Structure-activity relationships in prazosin-related compounds. 2. Role of the piperazine ring on alpha-blocking activity. J Med Chem 36:690-698.